- Conditions
- Acute Kidney Injury
- Interventions
- RMC-035, Placebo
- Drug
- Lead sponsor
- Guard Therapeutics AB
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 2,058
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
- Interventions
- Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
- Drug · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
- Conditions
- Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
- Interventions
- Epalrestat, Placebo
- Drug
- Lead sponsor
- Maggie's Pearl, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cancer-associated Cachexia
- Interventions
- Visugromab (CTL-002), Placebo
- Drug
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Norwich, Connecticut • Clermont, Florida • Orange City, Florida + 8 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Artesia, California • Pasadena, California • San Francisco, California + 3 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BEA 2180 BR, Tiotropium Bromide, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 2,080 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 56
- States / cities
- Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
- Conditions
- Parkinson Disease
- Interventions
- Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Arcadia, California • Loma Linda, California + 26 more
- Conditions
- Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Placebo, Enicepatide
- Drug
- Lead sponsor
- Carmot Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more
- Conditions
- Hypertension
- Interventions
- LFF269, Eplerenone, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 11
- States / cities
- Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more
- Conditions
- Malaria
- Interventions
- Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo
- Biological
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Gulf War Illness
- Interventions
- Concord grape juice, Placebo Beverage
- Dietary Supplement
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- East Orange, New Jersey
- Conditions
- Norovirus Gastroenteritis
- Interventions
- VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Alzheimer Disease
- Interventions
- ASN51, Placebo
- Drug
- Lead sponsor
- Asceneuron S.A.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 7
- States / cities
- Clermont, Florida • Lady Lake, Florida • Maitland, Florida + 4 more
- Conditions
- Muscle Tear
- Interventions
- ADRCs prepared by investigational Celution Device, Placebo
- Device · Biological
- Lead sponsor
- Cytori Therapeutics
- Industry
- Eligibility
- 20 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Healthy Participants
- Interventions
- Donzakimig, Placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Alzheimer Disease
- Interventions
- NTRX-07, Placebo
- Drug
- Lead sponsor
- NeuroTherapia, Inc.
- Industry
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Gates Mills, Ohio
- Conditions
- Cannabis Intoxication
- Interventions
- Cannabis, Pregnenolone 250 mg, Pregnenolone 500 mg, Placebo, Placebo brownie
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pharmacokinetics of Isavuconazole, Healthy Volunteers
- Interventions
- Isavuconazole, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Autism Spectrum Disorder, Challenging Behaviour, Aggression, Severe Disruptive Behaviour Disorders, Self-injury
- Interventions
- Propranolol, Placebo
- Drug
- Lead sponsor
- Jeremy Veenstra-vanderweele
- Other
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Staten Island, New York • White Plains, New York
- Conditions
- Degenerative Disc Disease
- Interventions
- IDCT, Saline Solution, Sodium Hyaluronate
- Biological · Drug
- Lead sponsor
- DiscGenics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Methamphetamine-dependence, Methamphetamine Abuse
- Interventions
- IXT-m200, Placebo
- Drug · Other
- Lead sponsor
- InterveXion Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • San Diego, California + 6 more
- Conditions
- Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
- Interventions
- Nicotinamide riboside
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- Obeticholic Acid (OCA), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Rialto, California • Sacramento, California • Miami, Florida + 8 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more